Adjuvant Chemotherapy for Colon Cancer: Use and Benefits
Author Information
Author(s): Bouchardy C, Queneau P-E, Fioretta G, Usel M, Zellweger M, Neyroud I, Raymond L, Wolf C de, Sappino A P
Primary Institution: Geneva Cancer Registry, Institute for Social and Preventive Medicine
Hypothesis
This study evaluates the use and benefit of adjuvant chemotherapy for stage III colon carcinoma in routine health care practice.
Conclusion
Adjuvant chemotherapy significantly decreased mortality rates in patients with stage III colon carcinoma, but its use is not optimal, especially among the elderly.
Supporting Evidence
- The use of chemotherapy increased over the study period.
- In 1996, 54% of eligible patients received chemotherapy, but this fell to 13% after age 70.
- Chemotherapy use significantly depended on stage, grade, and cancer site.
Takeaway
This study found that giving chemotherapy to people with a certain type of colon cancer helps them live longer, but not everyone who could get it is receiving it, especially older people.
Methodology
The study included patients with stage III colon carcinoma treated by surgery, analyzed chemotherapy use with logistic regression, and evaluated survival effects using the Cox model.
Potential Biases
The chance to be treated was lower among individuals of low social class, widowed, and foreigners, indicating potential bias in treatment decisions.
Limitations
The study may not reflect optimal chemotherapy utilization, particularly among elderly patients.
Participant Demographics
Patients with stage III colon carcinoma recorded at the Geneva cancer registry between 1990 and 1996.
Statistical Information
P-Value
0.35
Confidence Interval
95%CI: 0.18–0.68
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website